Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lower concentration of pazopanib linked with less toxicity

Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

Key clinical point: Trough concentrations of pazopanib in approximately the 20- to 50-mcg/mL range were associated with less toxicity but a similar overall response rate, versus higher concentrations.

Major finding: The overall response rate was about 46% in patients with pazopanib concentrations in that range, and in patients with higher concentrations. One patient in the “optimal” range experienced a grade 3 or greater toxicity.

Study details: An exploratory analysis including 27 patients with renal cell carcinoma.

Disclosures: The authors reported no conflicts of interest.

Read the article here.

Citation:

Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001.